

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-115)

LONAPEGSSOMATROPIN

PRONUNCIATION

loe" na peg soe" ma troe' pin

THERAPEUTIC CLAIM

Treatment of growth hormone deficiency

CHEMICAL NAMES

1. Poly(oxy-1,2-ethanediyl), $\alpha, \alpha', \alpha'', \alpha'''$ -[[[5-[4-[[[3-(dimethylamino)propyl]methylamino]carbonyl]oxy]phenyl]-5-(carboxyoxy)-1-oxopentyl]imino]bis[6,1-hexanediylthio(2,5-dioxo-3,1-pyrrolidinediyl)(1-oxo-3,1-propanediyl)imino-3,1-propanediyl]oxy-3,1,2-propanetriyl]]tetrakis[ω -methoxy-, amide with human somatotropin
2. Somatotropin (growth hormone) (*Homo sapiens*) statistically mono substituted on N^6 of lysine residues with the radical: {(1RS)-5-[bis(6-[(3RS)-1-{3-[(3-[(2RS)-2,3-bis[methoxypoly(ethyleneoxy)]propoxy}propyl)amino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl)hexyl)amino]-1-[4-({3-(dimethylamino)propyl]methylcarbonyl}oxy)phenyl]-5-oxopentoxo}carbonyl

STRUCTURAL FORMULA


Sequence

FPTIPLSRLF	DNAMLAHRL	HQLAFDTYQE	FEEAYIPKEQ	KYSFLQNPQT	50
SLCFSES IPT	PSNREETQQK	SNLELLRISL	LLIQSWLEPV	QFLRSVFANS	100
LVYGASDSNV	YDLLKDLEEG	IQTLMGRLED	GSPRTGQIFK	QTYSKFDTNS	150
HND DAL LKNY	GLLYCFRKDM	DKVETFLRIV	QCRSVEGSCG	F	191

Disulfide bridges location

53-165 182-189

Potential modified residues



MOLECULAR FORMULA

$\sim C_{1051}H_{1627}N_{269}O_{317}S_9[C_2H_4O]_{4n}$

MOLECULAR WEIGHT	67.4 kDa
TRADEMARK	None as yet
SPONSOR	Ascendis Pharma
CODE DESIGNATIONS	ACP-011, TransConPEG hGh, rhGH-PEG
<u>CAS</u> REGISTRY NUMBER	1934255-39-6
UNII	OP35X9610Y
WHO NUMBER	10598

gbk